Two cases of favorable response to combination therapy of photoimmunotherapy after administration of immune checkpoint inhibitors for recurrent head and neck cancer

DOI Web Site 10 References
  • Hayashi Yoshikazu
    Department of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyus
  • Hirakawa Hitoshi
    Department of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyus
  • Kinjyo Hidetoshi
    Department of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyus
  • Agena Shinya
    Department of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyus
  • Maeda Hiroyuki
    Department of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyus
  • Suzuki Mikio
    Department of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyus

Bibliographic Information

Other Title
  • 再発中咽頭癌および舌癌の頸部再発に対して免疫チェックポイント阻害薬治療後に光免疫療法が奏効した2例

Description

Photoimmunotherapy （PIT） is a treatment for unresectable locally advanced head and neck cancer or locally recurrent head and neck cancer that has become difficult to treat after standard therapies. PIT was approved in Japan in January 2021. PIT enhances the immune response and, when combined with immune checkpoint inhibitors （ICIs）, its effectiveness is amplified. This study presents two cases where PIT was highly effective after ICI treatment. The first case was a 69-year-old male with oropharyngeal squamous cell carcinoma and the second case was a 66-year-old male with recurrent anterior neck cancer. In both cases, complete response （CR） was maintained after one course of PIT for the residual disease following ICI. The combination of PIT and ICIs showed a synergistic effect. Although there is no consensus on the optimal timing for conducting PIT, these results suggest that PIT following ICI treatment may be a highly effective option.

Journal

References(10)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top